以患者为主导的尿酸盐自我监测改善痛风患者的临床疗效:可行性研究。

Toni J F Michael, Daniel F. B. Wright, Jian S Chan, M. Coleshill, Parisa Aslani, Dyfrig A. Hughes, Richard O Day, Sophie L Stocker
{"title":"以患者为主导的尿酸盐自我监测改善痛风患者的临床疗效:可行性研究。","authors":"Toni J F Michael, Daniel F. B. Wright, Jian S Chan, M. Coleshill, Parisa Aslani, Dyfrig A. Hughes, Richard O Day, Sophie L Stocker","doi":"10.1002/acr2.11666","DOIUrl":null,"url":null,"abstract":"OBJECTIVE\nSelf-monitored point-of-care urate-measuring devices are an underexplored strategy to improve adherence to urate-lowering therapy and clinical outcomes in gout. This study observed patient-led urate self-monitoring practice and assessed its influence on allopurinol adherence, urate control, and health-related quality of life.\n\n\nMETHODS\nPeople with gout (n = 31) and prescribed allopurinol self-monitored their urate concentrations (HumaSens2.0plus) at baseline and thereafter monthly for 12 months (3 months per quarter). Adherence to allopurinol was measured using medication event monitoring technology (Medication Event Monitoring System cap). Time spent below the target urate concentration (<0.36 mmol/L) was determined. Health-related quality of life was measured using a survey (EuroQoL EQ-5D-5L). Gout flares were recorded. Two-tailed Spearman correlation and the Wilcoxon matched-pairs signed-rank test (P < 0.05) were used for statistical comparisons.\n\n\nRESULTS\nMost participants were male (94%) and had urate concentrations below the target (74%) at baseline. Overall, seven participants demonstrated repeated periods of \"missed doses\" (two or fewer allopurinol doses missed consecutively) and \"drug holidays\" (three or more missed doses). Most participants (94%) persisted with allopurinol. Time spent within the target urate concentration increased 1.3-fold (from 79% to 100%; P = 0.346), and the incidence of gout flares decreased 1.6-fold (from 8 to 5; P = 0.25) in the final quarter compared to that in the first quarter of the study. Health-related quality of life was reduced for participants reporting at least one gout flare (median utility values 0.9309 vs 0.9563, P = 0.04).\n\n\nCONCLUSION\nPatient-led urate self-monitoring may support the maintenance of allopurinol adherence and improve urate control, thus reducing the incidence of gout flares. Further research on patient-led urate self-monitoring in a randomized controlled study is warranted.","PeriodicalId":7084,"journal":{"name":"ACR Open Rheumatology","volume":"130 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Patient-Led Urate Self-Monitoring to Improve Clinical Outcomes in People With Gout: A Feasibility Study.\",\"authors\":\"Toni J F Michael, Daniel F. B. Wright, Jian S Chan, M. Coleshill, Parisa Aslani, Dyfrig A. Hughes, Richard O Day, Sophie L Stocker\",\"doi\":\"10.1002/acr2.11666\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"OBJECTIVE\\nSelf-monitored point-of-care urate-measuring devices are an underexplored strategy to improve adherence to urate-lowering therapy and clinical outcomes in gout. This study observed patient-led urate self-monitoring practice and assessed its influence on allopurinol adherence, urate control, and health-related quality of life.\\n\\n\\nMETHODS\\nPeople with gout (n = 31) and prescribed allopurinol self-monitored their urate concentrations (HumaSens2.0plus) at baseline and thereafter monthly for 12 months (3 months per quarter). Adherence to allopurinol was measured using medication event monitoring technology (Medication Event Monitoring System cap). Time spent below the target urate concentration (<0.36 mmol/L) was determined. Health-related quality of life was measured using a survey (EuroQoL EQ-5D-5L). Gout flares were recorded. Two-tailed Spearman correlation and the Wilcoxon matched-pairs signed-rank test (P < 0.05) were used for statistical comparisons.\\n\\n\\nRESULTS\\nMost participants were male (94%) and had urate concentrations below the target (74%) at baseline. Overall, seven participants demonstrated repeated periods of \\\"missed doses\\\" (two or fewer allopurinol doses missed consecutively) and \\\"drug holidays\\\" (three or more missed doses). Most participants (94%) persisted with allopurinol. Time spent within the target urate concentration increased 1.3-fold (from 79% to 100%; P = 0.346), and the incidence of gout flares decreased 1.6-fold (from 8 to 5; P = 0.25) in the final quarter compared to that in the first quarter of the study. Health-related quality of life was reduced for participants reporting at least one gout flare (median utility values 0.9309 vs 0.9563, P = 0.04).\\n\\n\\nCONCLUSION\\nPatient-led urate self-monitoring may support the maintenance of allopurinol adherence and improve urate control, thus reducing the incidence of gout flares. Further research on patient-led urate self-monitoring in a randomized controlled study is warranted.\",\"PeriodicalId\":7084,\"journal\":{\"name\":\"ACR Open Rheumatology\",\"volume\":\"130 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACR Open Rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/acr2.11666\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACR Open Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/acr2.11666","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的自我监测的护理点尿酸测量装置是一种尚未得到充分探索的策略,可提高痛风患者坚持降尿酸治疗的依从性和临床疗效。本研究观察了由患者主导的尿酸盐自我监测实践,并评估了其对别嘌呤醇依从性、尿酸盐控制和与健康相关的生活质量的影响。方法痛风患者(31 人)开具别嘌呤醇处方后,在基线时自我监测尿酸盐浓度(HumaSens2.0plus),此后每月监测一次,持续 12 个月(每季度 3 个月)。使用用药事件监测技术(用药事件监测系统帽)对别嘌呤醇的依从性进行测量。测定低于目标尿酸浓度(<0.36 mmol/L)的时间。使用一项调查(EuroQoL EQ-5D-5L)测量与健康相关的生活质量。记录痛风发作情况。结果大多数参与者为男性(94%),基线尿酸盐浓度低于目标值(74%)。总体而言,有 7 名参与者反复出现 "漏服"(连续漏服两剂或两剂以下别嘌醇)和 "药物假期"(漏服三剂或三剂以上)。大多数参与者(94%)坚持服用别嘌醇。与研究的第一季度相比,最后一个季度尿酸浓度在目标值范围内的时间增加了1.3倍(从79%增至100%;P = 0.346),痛风发作的发生率降低了1.6倍(从8次降至5次;P = 0.25)。结论患者主导的尿酸自我监测可帮助患者坚持服用别嘌醇并改善尿酸控制,从而降低痛风发作率。有必要在随机对照研究中对患者主导的尿酸盐自我监测进行进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Patient-Led Urate Self-Monitoring to Improve Clinical Outcomes in People With Gout: A Feasibility Study.
OBJECTIVE Self-monitored point-of-care urate-measuring devices are an underexplored strategy to improve adherence to urate-lowering therapy and clinical outcomes in gout. This study observed patient-led urate self-monitoring practice and assessed its influence on allopurinol adherence, urate control, and health-related quality of life. METHODS People with gout (n = 31) and prescribed allopurinol self-monitored their urate concentrations (HumaSens2.0plus) at baseline and thereafter monthly for 12 months (3 months per quarter). Adherence to allopurinol was measured using medication event monitoring technology (Medication Event Monitoring System cap). Time spent below the target urate concentration (<0.36 mmol/L) was determined. Health-related quality of life was measured using a survey (EuroQoL EQ-5D-5L). Gout flares were recorded. Two-tailed Spearman correlation and the Wilcoxon matched-pairs signed-rank test (P < 0.05) were used for statistical comparisons. RESULTS Most participants were male (94%) and had urate concentrations below the target (74%) at baseline. Overall, seven participants demonstrated repeated periods of "missed doses" (two or fewer allopurinol doses missed consecutively) and "drug holidays" (three or more missed doses). Most participants (94%) persisted with allopurinol. Time spent within the target urate concentration increased 1.3-fold (from 79% to 100%; P = 0.346), and the incidence of gout flares decreased 1.6-fold (from 8 to 5; P = 0.25) in the final quarter compared to that in the first quarter of the study. Health-related quality of life was reduced for participants reporting at least one gout flare (median utility values 0.9309 vs 0.9563, P = 0.04). CONCLUSION Patient-led urate self-monitoring may support the maintenance of allopurinol adherence and improve urate control, thus reducing the incidence of gout flares. Further research on patient-led urate self-monitoring in a randomized controlled study is warranted.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Redox Pathogenesis in Rheumatic Diseases. Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota. CD14+ Dendritic-Shaped Cells Functioning as Dendritic Cells in Rheumatoid Arthritis Synovial Tissues. Patient-Led Urate Self-Monitoring to Improve Clinical Outcomes in People With Gout: A Feasibility Study. Detection and Grading of Radiographic Hand Osteoarthritis Using an Automated Machine Learning Platform.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1